全文获取类型
收费全文 | 15172篇 |
免费 | 1068篇 |
国内免费 | 49篇 |
学科分类
医药卫生 | 16289篇 |
出版年
2023年 | 65篇 |
2022年 | 107篇 |
2021年 | 249篇 |
2020年 | 205篇 |
2019年 | 296篇 |
2018年 | 358篇 |
2017年 | 219篇 |
2016年 | 276篇 |
2015年 | 291篇 |
2014年 | 443篇 |
2013年 | 673篇 |
2012年 | 1018篇 |
2011年 | 1013篇 |
2010年 | 572篇 |
2009年 | 570篇 |
2008年 | 936篇 |
2007年 | 1017篇 |
2006年 | 904篇 |
2005年 | 974篇 |
2004年 | 931篇 |
2003年 | 907篇 |
2002年 | 794篇 |
2001年 | 204篇 |
2000年 | 185篇 |
1999年 | 185篇 |
1998年 | 161篇 |
1997年 | 160篇 |
1996年 | 143篇 |
1995年 | 121篇 |
1994年 | 98篇 |
1993年 | 103篇 |
1992年 | 124篇 |
1991年 | 112篇 |
1990年 | 91篇 |
1989年 | 109篇 |
1988年 | 93篇 |
1987年 | 91篇 |
1986年 | 84篇 |
1985年 | 113篇 |
1984年 | 87篇 |
1983年 | 85篇 |
1982年 | 89篇 |
1981年 | 85篇 |
1980年 | 76篇 |
1979年 | 64篇 |
1978年 | 87篇 |
1977年 | 68篇 |
1976年 | 52篇 |
1975年 | 51篇 |
1974年 | 45篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
New Zealand Emergency Medicine Network: A collaboration for acute care research in New Zealand 下载免费PDF全文
The specialty of emergency medicine in Australasia is coming of age. As part of this maturation there is a need for high‐quality evidence to inform practice. This article describes the development of the New Zealand Emergency Medicine Network, a collaboration of committed emergency care researchers who share the vision that New Zealand/Aotearoa will have a world‐leading, patient‐centred emergency care research network, which will improve emergency care for all, so that people coming to any ED in the country will have access to the same world‐class emergency care. 相似文献
2.
3.
4.
5.
Bone mineral density testing in healthy postmenopausal women. The role of clinical risk factor assessment in determining fracture risk. 总被引:5,自引:0,他引:5
William D Leslie Colleen Metge Elizabeth A Salamon C Kin Yuen 《Journal of clinical densitometry》2002,5(2):117-130
The ease of measurement and the quantitative nature of bone mineral densitometry (BMD) is clinically appealing. Despite BMD's proven capability to stratify fracture risk, data indicate that clinical risk factors provide complementary information on fracture susceptibility that is independent of BMD. Methods to quantify fracture risk using both clinical and BMD variables would have great appeal for clinical decision-making. We describe a procedure for quantifying hip fracture risk (5-yr and remaining lifetime) based on (1) the individual's age alone (base model, assuming average clinical risk factors and bone density), (2) incorporation of multiple patient-specific clinical risk factor data in the base model, and (3) incorporation of both patient-specific clinical risk factor data and BMD results. 相似文献
6.
7.
8.
Bill J Gurley Ashley Swain Gary W Barone D Keith Williams Philip Breen C Ryan Yates Leslie B Stuart Martha A Hubbard Yudong Tong Sreekhar Cheboyina 《Drug metabolism and disposition》2007,35(2):240-245
Phytochemical-mediated modulation of P-glycoprotein (P-gp) and other drug transporters may give rise to many herb-drug interactions. Serial plasma concentration-time profiles of the P-gp substrate, digoxin, were used to determine whether supplementation with goldenseal or kava kava modified P-gp activity in vivo. Twenty healthy volunteers were randomly assigned to receive a standardized goldenseal (3210 mg daily) or kava kava (1227 mg daily) supplement for 14 days, followed by a 30-day washout period. Subjects were also randomized to receive rifampin (600 mg daily, 7 days) and clarithromycin (1000 mg daily, 7 days) as positive controls for P-gp induction and inhibition, respectively. Digoxin (Lanoxin, 0.5 mg) was administered p.o. before and at the end of each supplementation and control period. Serial digoxin plasma concentrations were obtained over 24 h and analyzed by chemiluminescent immunoassay. Comparisons of area under the curve (AUC)((0-3)), AUC((0-24)), C(max,) CL/F, and elimination half-life were used to assess the effects of goldenseal, kava kava, rifampin, and clarithromycin on digoxin pharmacokinetics. Rifampin produced significant reductions (p < 0.01) in AUC((0-3)), AUC((0-24)), CL/F, t(1/2), and C(max), whereas clarithromycin increased these parameters significantly (p < 0.01). With the exception of goldenseal's effect on C(max) (14% increase), no statistically significant effects on digoxin pharmacokinetics were observed following supplementation with either goldenseal or kava kava. When compared with rifampin and clarithromycin, supplementation with these specific formulations of goldenseal or kava kava did not appear to affect digoxin pharmacokinetics, suggesting that these supplements are not potent modulators of P-gp in vivo. 相似文献
9.
Practical management of patients with non-small-cell lung cancer treated with gefitinib. 总被引:7,自引:0,他引:7
Neelam T Shah Mark G Kris William Pao Leslie B Tyson Barbara M Pizzo Murk-Hein Heinemann Leah Ben-Porat Dana L Sachs Robert T Heelan Vincent A Miller 《Journal of clinical oncology》2005,23(1):165-174
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. 相似文献
10.